Forigerimod TFA
Based on 1 Customer Validation
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.88%
- Fòrmula: C117H181N34O32PS.xC2HF3O2
-
Almacenamiento:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MRL/lpr mice[4]
-
Dosage:100 μg in 100 μL saline per mouse
-
Administration:Intravenous administration, single
-
Result:Corrected the cell content and distribution in MRL/lpr salivary glands.
Corrected the defective of autophagy processes in SGs of MRL/lpr mice.
Chemical Information
-
Appearance Solid
-
Fòrmula C117H181N34O32PS.xC2HF3O2
-
Color White to off-white
-
Synonyms
IPP-201101 TFA
-
Sequence Shortening
RIHMVYSKR-{pSer}-GKPRGYAFIEY (TFA)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Solvente y solubilidad
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (Need ultrasonic)
Pureza y Documentación
-
Ficha de datos (268 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Aikaterini Thanou, et al. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. [Content Brief]
[2]. Sean Robinson, et al. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front Immunol. 2021 Jul 16;12:654701. [Content Brief]
[3]. Robert Zimmer, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013 Nov;72(11):1830-5. [Content Brief]
[4]. Baihui Li, et al. Rescue of autophagy and lysosome defects in salivary glands of MRL/lpr mice by a therapeutic phosphopeptide. J Autoimmun. 2018 Jun;90:132-145. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Forigerimod TFA Related Classifications
HY-105037A Related Classifications
Powered by Bioz